Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

DOI: https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

DOI: https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 2869.

DOI: https://doi.org/10.1182/blood-2019-125939

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

DOI: https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

DOI: https://doi.org/10.1182/blood-2019-125990

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

DOI: https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Peter Johnson, MDFRCP, Sriram Balasubramanian, Brendan Hodkinson, Michael Schaffer, Lori Parisi, S. Martin Shreeve, Steven Sun, Jessica Vermeulen, Laurie H Sehn, MD, Louis Staudt, Anas Younes, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 354.

DOI: https://doi.org/10.1182/blood-2019-124443

Published: 2019

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

DOI: https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

Viral, immunologic, and clinical features of primary effusion lymphoma

Kathryn Lurain, Mark N. Polizzotto, Karen Aleman, Manisha Bhutani, Kathleen M. Wyvill, Priscila H. Gonçalves, Ramya Ramaswami, Vickie Ann Marshall, Wendell Miley, Seth M. Steinberg, Richard F. Little, Wyndham Wilson, Armando C. Filie, Stefania Pittaluga, Elaine S. Jaffe, Denise Whitby, Robert Yarchoan, Thomas S. Uldrick

Blood (2019) 133 (16): 1753–1761.

DOI: https://doi.org/10.1182/blood-2019-01-893339

Published: 2019

Journal Articles

Ongoing Activation of the BCR, NFκB, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironnment

Nakhle Saba, MD, Delong Liu, PhD, Sarah E. M. Herman, PhD, Cliona Grant, MD, Kieron Dunleavy, MD, Stefania Pittaluga, Wyndham Wilson, MD PhD, Adrian Wiestner, MD PhD

Blood (2014) 124 (21): 2991.

DOI: https://doi.org/10.1182/blood.V124.21.2991.2991

Published: 2014

Journal Articles

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, Laurence Elias

Blood (2013) 122 (14): 2412–2424.

DOI: https://doi.org/10.1182/blood-2013-02-482125

Published: 2013

Includes: Supplemental data

Journal Articles

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States

Blood (2011) 117 (22): 5835–5849.

DOI: https://doi.org/10.1182/blood-2010-11-316745

Published: 2011

Includes: Supplemental data

Journal Articles

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

Blood (2010) 116 (7): 1025–1034.

DOI: https://doi.org/10.1182/blood-2009-12-257485

Published: 2010

Includes: Supplemental data

Journal Articles

Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.

Violetta Leshchenko, PhD, Pei-Yu Kuo, MS, Rita Shaknovich, MD, PhD, Tobias Gellen, Yvonne Remache, BS, Marc Weniger, PhD, K. Stephen Suh, PhD, Andre Goy, MD, Wyndham Wilson, MD, PhD, Ira Braunschweig, MD, Amit Verma, MD, Adrian Wiestner, MD, PhD, Ari Melnick, MD, Samir Parekh, MD

Blood (2009) 114 (22): 673.

DOI: https://doi.org/10.1182/blood.V114.22.673.673

Published: 2009

Journal Articles

Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma

Blood (2008) 112 (11): 475.

DOI: https://doi.org/10.1182/blood.V112.11.475.475

Published: 2008

Journal Articles

Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor

James Kochenderfer, M.D., Steven Feldman, PhD, Yangbing Zhao, PhD, Hui Xu, Mary Black, Richard Morgan, PhD, Mark Dudley, PhD, Wyndham Wilson, MD, PhD, Steven Rosenberg, MD, PhD

Blood (2008) 112 (11): 4623.

DOI: https://doi.org/10.1182/blood.V112.11.4623.4623

Published: 2008

Journal Articles

A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin’s Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy.

Dan L. Longo, Eli Glatstein, Patricia L. Duffey, Robert C. Young, Shelby Fiem, Elaine S. Jaffe, Kevin Camphausen, Wyndham Wilson, Vincent T. DeVita

Blood (2006) 108 (11): 98.

DOI: https://doi.org/10.1182/blood.V108.11.98.98

Published: 2006

Journal Articles

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Edgar G. Rizzatti, MD, PhD, Helena Mora-Jensen, BS, Raymond Lai, MD/PhD, Masanori Daibata, MD, Therese White, RN, Kieron Dunleavy, MD, Wyndham Wilson, MD/PhD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 830.

DOI: https://doi.org/10.1182/blood.V108.11.830.830

Published: 2006

Journal Articles

ZAP-70 Expression Is Associated with Increased Migration to SDF-1 in Chronic Lymphocytic Leukemia.

Yuji Miura, MD, PhD, Elinor Lee, BA, Federica Gibellini, PhD, Therese White, RN, Gerald Marti, MD, Wyndham Wilson, MD/PhD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 587.

DOI: https://doi.org/10.1182/blood.V108.11.587.587

Published: 2006

Journal Articles

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

Robin A. Roberts, BS, Lisa M. Rimsza, M.D., Louis Staudt, M.D.Ph.D., Andreas Rosenwald, M.D., Wing-Chung Chan, M.D., Sandeep Dave, M.D., Randy D. Gascoyne, M.D., Joseph M. Connors, M.D., Erlend B. Smeland, M.D.Ph.D., H.K. Muller-Hermelink, M.D., Elias Campo, M.D., Elaine S. Jaffe, M.D., Wyndham Wilson, M.D., Bruce K. Tan, M.D., Richard I. Fisher, M.D., Thomas M. Grogan, M.D., Thomas P. Miller, MD

Blood (2006) 108 (11): 809.

DOI: https://doi.org/10.1182/blood.V108.11.809.809

Published: 2006

NARROW

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Viral, immunologic, and clinical features of primary effusion lymphoma

Ongoing Activation of the BCR, NFκB, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironnment

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.

Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma

Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor

A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin’s Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy.

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

ZAP-70 Expression Is Associated with Increased Migration to SDF-1 in Chronic Lymphocytic Leukemia.

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only